Minerva Surgical, Inc. (UTRS): Price and Financial Metrics


Minerva Surgical, Inc. (UTRS): $2.35

0.12 (+5.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

UTRS Stock Price Chart Interactive Chart >

Price chart for UTRS

UTRS Price/Volume Stats

Current price $2.35 52-week high $10.37
Prev. close $2.23 52-week low $1.61
Day low $2.23 Volume 11,700
Day high $2.38 Avg. volume 42,663
50-day MA $3.91 Dividend yield N/A
200-day MA $0.00 Market Cap 67.76M

Minerva Surgical, Inc. (UTRS) Company Bio


Minerva Surgical Inc., a commercial-stage medical technology company, focuses on developing, manufacturing, and commercializing minimally invasive solutions to meet the uterine healthcare needs of women. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists across various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.


UTRS Latest News Stream


Event/Time News Detail
Loading, please wait...

UTRS Latest Social Stream


Loading social stream, please wait...

View Full UTRS Social Stream

Latest UTRS News From Around the Web

Below are the latest news stories about Minerva Surgical Inc that investors may wish to consider to help them evaluate UTRS as an investment opportunity.

Minerva Surgical to Announce Fourth Quarter and Full-Year Financial Results

SANTA CLARA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full-year 2021 financial results on Tuesday, March 8, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Yahoo | February 22, 2022

Minerva Surgical to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SANTA CLARA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 3:40 p.m. Eastern Time. A live audio webcast and replay of the presentation may be accessed through the “Recent Events” section of Minerva’s website at http://ir.minervasurgica

Yahoo | January 31, 2022

Minerva Surgical, Inc.'s (NASDAQ:UTRS) recent US$21m market cap decline means a loss of US$3.3k for insiders who bought this year

The recent price decline of 13% in Minerva Surgical, Inc.'s ( NASDAQ:UTRS ) stock may have disappointed insiders who...

Yahoo | January 25, 2022

Minerva Surgical's Preliminary FY21 Revenues Top Expectations

View more earnings on UTRSSee more from BenzingaB. Riley Beefs Up Intercept Target Price On Catalyst Rich 1H 2022Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Yahoo | January 12, 2022

Minerva Surgical Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

SANTA CLARA, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a medical device company that has established a broad product line of commercially available, minimally invasive medical devices that address the most common causes of abnormal uterine bleeding (AUB) as alternatives to hysterectomy, today reported preliminary unaudited fourth quarter and full year 2021 revenue expectations. Preliminary Fourth Quarter and Full Year 2021

Yahoo | January 11, 2022

Read More 'UTRS' Stories Here

UTRS Price Returns

1-mo -44.71%
3-mo -55.24%
6-mo -71.52%
1-year N/A
3-year N/A
5-year N/A
YTD -54.28%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5512 seconds.